Compare FFWM & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FFWM | ADCT |
|---|---|---|
| Founded | 1990 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 498.1M | 439.8M |
| IPO Year | 2014 | 2020 |
| Metric | FFWM | ADCT |
|---|---|---|
| Price | $6.05 | $3.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $6.17 | ★ $7.60 |
| AVG Volume (30 Days) | ★ 637.5K | 582.0K |
| Earning Date | 01-29-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $159,621,000.00 | $75,209,000.00 |
| Revenue This Year | $166.48 | $12.48 |
| Revenue Next Year | $6.86 | $5.12 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 47.55 | 6.35 |
| 52 Week Low | $4.42 | $1.05 |
| 52 Week High | $6.54 | $4.80 |
| Indicator | FFWM | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 46.78 | 38.09 |
| Support Level | $5.89 | $3.51 |
| Resistance Level | $6.28 | $3.64 |
| Average True Range (ATR) | 0.21 | 0.21 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 18.46 | 0.54 |
First Foundation Inc is a financial services company. It is engaged in providing investment management and financial planning services for high-net-worth individuals, retirement plans, charitable institutions, and private foundations. The company focuses on segments namely Banking and Wealth Management. It also offers loans to individuals and entities that own and operate multifamily residential and commercial real estate properties as well as business banking products and services to small to moderate-sized businesses, professional firms, and consumer banking products and services to individuals.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).